Document is current

Article History

Received: 10 November 2023

Accepted: 1 December 2023

First Online: 4 January 2024

Declarations

:

: Not applicable.

: Not applicable.

: ML: Associate Editor of The Journal of Headache and Pain. PM: Editor-in-Chief of The Journal of Headache and Pain and of SN Comprehensive Clinical Medicine; EU Expert, European Medicines Agency. RB: research support from the NIH, Allergan, Teva, Dr. Ready, Eli Lilly, Trigeminal and the Migraine Research Foundation. He is a reviewer for NINDS, holds stock options in AllayLamp, Theranica and Percept; serves as consultant, advisory board member, or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP diagnostic, Dr. Reddy’s Laboratory, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Theranica, Teva, and Trigemina; CME fees from Healthlogix, Medlogix, WebMD/Medscape, and Patents 9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497. LG: consultancy and advisory fees from Abbvie-AllerganSpA, Lundbeck, Novartis, EliLilly, TEVA Pharm, Pfizer. AG: Elected Trustee, World Federation of Neurology; Treasurer, International League against Epilepsy; Board member: Neurological Sciences (associate editor), European Journal of Neurology, Epilepsy and Behavior, Journal of Neurological Sciences. RL: has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy’s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from Wolff’s Headache, 8th edition (Oxford University Press, 2009), and Informa. He holds stock in Biohaven and Manistee. DDM: honoraria, research, and travel grants from Allergan/Abbvie, Amgen, Biogen, Cefaly, Genesis Pharma, Eli Lilly, Electrocore, Lundbeck, Mertz, Merk-Serono, Novartis, Roche, Sanofi, Specifar, and Teva; he participated in clinical trials for Amgen, Novartis, Cefaly, Eli Lilly, Electrocore, Genesis Pharma, Lundbeck, Mertz, Specifar, and Teva as principal investigator; he is President of the Hellenic Headache Society and Co-chairman of the Headache Scientific Panel at the European Academy of Neurology. JO: stock owner in Cephagenix and Lundbeck. SS: personal fees as speaker or advisor by Abbott, Allergan-Abbvie, AstraZeneca, Boheringer, Eli Lilly, Lundbeck, Novartis, NovoNordisk, Pfizer, Teva; research grants by Novartis, Uriach; president elect European Stroke Organization, second vice president of the European Headache Federation, specialty chief editor in Headache and Neurogenic Pain for Frontiers in Neurology, associate editor for The Journal of Headache and Pain, assistant editor for Stroke. TJS: Director of the Global Campaign against Headache. NS: Chairman, Surya Neuro Center; Founder Trustee & Chairman, Epilepsy Foundation India; Fellow, Indian Academy of Neurology; Member, Academy of Medical Sciences; Fellow, American Academy of Neurology; President, Indian Federation Of Neuro - Rehabilitation (IFNR); Regional Vice President, World Federation Neuro-Rehabilitation (WFNR); Past President, Indian Academy of Neurology (IAN); President Elect, Indian Stroke Association (ISA); Chair, Developing World Forum; President Elect, Asian Oceanian Society of Neurorehabilitation (AOSNR); Chair, Telemedicine Academy Indian Confederation For Healthcare Accreditation (ICHA); Member, Digital Strategy Subcommittee (DSS) American Academy of Neurology (AAN 2021-2023); President, WCNR2018Mumbai; Treasurer, Indian Academy of Neurology (IAN) 2014-2020; Executive Member, Indian Stroke Association (2018-2021); Past President, Bombay Neurosciences Association; Past President, Maharastra Association of Neurology. TT: Takao Takeshima is a consultant/advisor for Hedgehog MedTech and Sawai, and has received speaker honoraria from Eli Lilly, Daiichi Sankyo, Otsuka, Amgen. CT: honoraria for the participation in advisor boards or for speaking in scientific symposia from Allergan/Abbvie, Dompé, Eli Lilly, Novartis, Lundbeck, Pfizer, Biohaven, Teva, WebMD; research support from AbbVie, Dompé, Migraine Research Foundation, Italian Ministry of Health, EU Commission; payments for Clinical trials from Allergan/Abbvie, Amgen, Lilly, Novartis, Lundbeck, Pfizer, Biohaven and Teva; she is President of the International Headache Society and co-sponsor of the initiative ‘Headache research Priorities’ in collaboration with AHS. S-JW: honoraria as a moderator from AbbVie, Pfizer, Eli Lilly and Biogen; PI in trials sponsored by AbbVie, Novartis, Eli Lilly and Lundbeck; Research grants from the Taiwan National Science and Technology Council, Brain Research Center, National Yang Ming Chiao Tung University from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Taipei Veterans General Hospital, Taiwan Headache Society and Taiwan branches of Eli Lillyand Novartis. AR: editorial board member of The Journal of Headache and Pain. AF, MOO, ERdlT, and TW declare no competing interests.